Sustained Therapeutics is an early-stage company utilizing its advanced clinical and research expertise to develop non-opioid locally injected sustained-release therapeutics primarily for the treatment of pain. Our novel sustained-release drug delivery platform has the potential to provide effective, long-lasting solutions for managing both acute and chronic pain. In the longer term we believe that our platform can also support the development of therapeutics for fibrotic, urological and inflammatory diseases, as well as some types of cancer.

Sustained Therapeutics’ patented drug delivery platform is a non-opioid approach designed to relieve acute and chronic pain in a highly controlled way over longer periods with fewer side effects. Sustained's products have a significant competitive advantage, offering up to four weeks of pain relief from a single injection compared to only one to three days for competitive products. In addition they are non-addictive, unlike opioid drugs.

A successful Phase I clinical trial completed in 2021 demonstrated the feasibility of Sustained's approach. Two Phase II studies are now underway, one in acute post-operative pain and a second in Chronic Scrotal Pain. We anticipate initiating a third Phase II trial in Chronic Pelvic Pain in early 2024.

In addition we are finalizing a second product, this one focused on cancer. We are planning on launching a Phase II trial in Upper Tract Urothelial Carcinoma, an orphan disease, and anticipate a start date in Q4 2023.